INTRODUCTION AND OBJECTIVES:
In a large multicenter series, we assessed the impact of performing a standard systematic sampling of the prostate in addition to mpMRI-targeted biopsies, in terms of prostate cancer (PCa) and clinically significant (cs) PCa detection.
METHODS: We retrospectively enrolled 1.119 patients out of a multicenter retrospective database of 2.115 mpMRI-targeted biopsies. Biopsies were performed using the Koelis TM platform between 2010 and 2017 and consisted in targeted (median 3 cores per target) and systematic (12 to 14 cores) sampling. Overall and csPCa detection rate (CDR) of both target and systematic biopsies represented our primary outcomes. We also investigated potential predictors of PCa detection.
RESULTS: Targeted cores alone detected PCa in about half of the patients undergoing biopsy (48%), while csPCa was diagnosed in one-third (33%). The addition of a systematic sampling improved detection by 15% for all cancers and by 12% for csPCa. Lesion scored as PI-RADS 3, 4 and 5 corresponded to 35%, 69%, and 92% of PCa detection rates, respectively. Higher PI-RADS score and positive digital rectal examination were positively associated with PCa diagnosis, whereas biopsy-naive status was a predictor of csPCa.
CONCLUSIONS: Targeted biopsies attain high CDR for both every PCa and csPCa, in daily practice; nevertheless, the addition of a systematic sampling of the gland significantly improves detection rate. Patients with an elevated PI-RADS score and/or a positive DRE had a significantly increased risk to be diagnosed with PCa. Moreover, csPCa detection was associated with a biopsy-naive status.
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MP30-06 MULTI-PARAMETRIC PROSTATE MRI AS A SCREENING TEST AMONG MALE BRCA CARRIERS
David Margel*, Sivan Sela, Shlomit Tamir, Inbal Kedar, Yaara Ber, Daniel Kedar, Andrei Nadu, Jack Baniel, Petah-Tikva, Israel INTRODUCTION AND OBJECTIVES: Male BRCA germline mutation carriers are at high risk for prostate cancer. IMPACT study results support routine PSA screening among BRCA carriers. Guidelines for female BRCA carriers include breast MRI as part of routine cancer screening. In this study we examine the use of MRI as a screening tool for prostate cancer among male BRCA carriers.
METHODS: We prospectively enrolled 185 male BRCA carriers age 40-70, between April 2014-July 2018. We performed the following screening for all male BRCA carriers: DRE, PSA and multi-parametric prostate MRI. We performed MRI-US fusion biopsies to any suspicious lesion.
RESULTS: Of the 185 BRCA carriers included, 107 had a BRCA1 mutation (58%) and 78 BRCA2 mutations (42%). Median age
